A detailed history of Ubs Asset Management Americas Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 460,012 shares of NTLA stock, worth $5.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
460,012
Previous 512,309 10.21%
Holding current value
$5.6 Million
Previous $11.5 Million 17.55%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.72 - $27.36 $1.03 Million - $1.43 Million
-52,297 Reduced 10.21%
460,012 $9.45 Million
Q2 2024

Aug 13, 2024

BUY
$20.02 - $27.22 $2.66 Million - $3.61 Million
132,671 Added 34.95%
512,309 $11.5 Million
Q1 2024

May 15, 2024

SELL
$23.82 - $32.8 $1.25 Million - $1.72 Million
-52,374 Reduced 12.12%
379,638 $10.4 Million
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $570,361 - $796,437
24,627 Added 6.05%
432,012 $13.2 Million
Q3 2023

Nov 13, 2023

SELL
$31.62 - $45.78 $358,570 - $519,145
-11,340 Reduced 2.71%
407,385 $12.9 Million
Q1 2023

May 15, 2023

BUY
$33.3 - $44.82 $848,517 - $1.14 Million
25,481 Added 6.48%
418,725 $15.6 Million
Q4 2022

Feb 14, 2023

SELL
$33.21 - $62.69 $326,487 - $616,305
-9,831 Reduced 2.44%
393,244 $13.7 Million
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $1.71 Million - $2.27 Million
31,670 Added 8.53%
403,075 $22.6 Million
Q2 2022

Aug 12, 2022

BUY
$38.49 - $76.21 $2 Million - $3.96 Million
52,001 Added 16.28%
371,405 $19.2 Million
Q1 2022

May 16, 2022

BUY
$58.27 - $118.99 $1.8 Million - $3.67 Million
30,815 Added 10.68%
319,404 $23.2 Million
Q4 2021

Feb 14, 2022

SELL
$100.76 - $138.36 $73,252 - $100,587
-727 Reduced 0.25%
288,589 $34.1 Million
Q3 2021

Nov 15, 2021

BUY
$132.37 - $176.78 $2.09 Million - $2.8 Million
15,824 Added 5.79%
289,316 $38.8 Million
Q2 2021

Aug 16, 2021

BUY
$60.88 - $161.91 $2.58 Million - $6.85 Million
42,301 Added 18.3%
273,492 $44.3 Million
Q1 2021

May 14, 2021

SELL
$46.59 - $83.68 $2.32 Million - $4.17 Million
-49,808 Reduced 17.73%
231,191 $18.6 Million
Q4 2020

Mar 01, 2021

BUY
$18.83 - $63.53 $4.07 Million - $13.7 Million
215,922 Added 331.79%
280,999 $15.3 Million
Q3 2020

Nov 13, 2020

BUY
$17.47 - $24.93 $89,725 - $128,040
5,136 Added 8.57%
65,077 $1.29 Million
Q2 2020

Aug 14, 2020

BUY
$11.14 - $22.87 $124,188 - $254,954
11,148 Added 22.85%
59,941 $1.26 Million
Q1 2020

May 15, 2020

BUY
$9.44 - $15.58 $72,216 - $119,187
7,650 Added 18.59%
48,793 $596,000
Q4 2019

Feb 14, 2020

SELL
$10.43 - $17.67 $18,242 - $30,904
-1,749 Reduced 4.08%
41,143 $603,000
Q3 2019

Nov 14, 2019

BUY
$13.07 - $18.51 $322,005 - $456,030
24,637 Added 134.96%
42,892 $572,000
Q2 2019

Aug 15, 2019

BUY
$13.88 - $18.41 $253,379 - $336,074
18,255 New
18,255 $0
Q4 2018

Feb 13, 2019

SELL
$11.39 - $27.13 $98,352 - $234,267
-8,635 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$25.78 - $32.6 $222,610 - $281,501
8,635 New
8,635 $0

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.